Egrifta Disease Interactions

The use of tesamorelin is contraindicated in patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma and in patients with active malignancy.

The use of tesamorelin can result in glucose intolerance. Tesamorelin increases insulin-like growth factor-1 (IGF-1). It is recommended to evaluate glucose status prior to initiation of therapy and to monitor periodically during treatment. Therapy discontinuation may be considered in patients that do not show a clear efficacy response and develop glucose intolerance or diabetes. Diabetes patients should be monitored for potential development or worsening of retinopathy. Care should be exercised when using this agent in patients with diabetes.

The use of tesamorelin may cause fluid retention related to the induction of growth hormone secretion. This manifests as increased tissue turgor and musculoskeletal discomfort resulting in adverse reactions (e.g. edema, arthralgia, and carpal tunnel syndrome) which are either transient or resolve with discontinuation of treatment. Care should be exercised when using tesamorelin in patients at risks for fluid retention.